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The most consistent finding derived from the WTCCC GWAS for rheumatoid arthritis (RA) was association to
a SNP at 6q23. We performed a fine-mapping of the region in order to search the 6q23 region for additional
disease variants. 3962 RA patients and 3531 healthy controls were included in the study. We found 18 SNPs
associated with RA. The SNP showing the strongest association was rs6920220 [P 5 2.63 1026, OR (95% CI)
1.22 (1.13–1.33)]. The next most strongly associated SNP was rs13207033 [P 5 0.0001, OR (95% CI) 0.86 (0.8–
0.93)] which was perfectly correlated with rs10499194, a SNP previously associated with RA in a US/European
series. Additionally, we found a number of new potential RA markers, including rs5029937, located in the
intron 2 of TNFAIP3. Of the 18 associated SNPs, three polymorphisms, rs6920220, rs13207033 and
rs5029937, remained significant after conditional logistic regression analysis. The combination of the car-
riage of both risk alleles of rs6920220 and rs5029937 together with the absence of the protective allele of
rs13207033 was strongly associated with RA when compared with carriage of none [OR of 1.86 (95% CI)
(1.51–2.29)]. This equates to an effect size of 1.50 (95% CI 1.21–1.85) compared with controls and is
higher than that obtained for any SNP individually. This is the first study to show that the confirmed loci
from the GWA studies, that confer only a modest effect size, could harbour a significantly greater effect
once the effect of additional risk variants are accounted for.
INTRODUCTION
Rheumatoid arthritis [RA, (MIM #180300)] is an autoimmune
inflammatory disease characterized by inflammation and
destruction of synovial joints leading to progressive joint
damage and disability. It is the most common inflammatory
arthritis, affecting up to 1% of the population worldwide (1).
Although RA aetiology is not yet fully understood, it is known
that a strong genetic component plays a major role in disease
susceptibility, together with environmental factors (2).
The Wellcome Trust Case Control Consortium (WTCCC)
identified, through a genome-wide association study (GWAS),
†The authors wish it to be known that, in their opinion, the first two authors should be regarded as joint First Authors.
To whom correspondence should be addressed. Tel: þ44 1612751674; Fax: þ44 1612755043; Email: gisela.orozco@manchester.ac.uk
‡Supplementary note online.
# 2009 The Author(s).
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/
licenses/by-nc/2.0/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Human Molecular Genetics, 2009, Vol. 18, No. 14 2693–2699
doi:10.1093/hmg/ddp193
Advance Access published on May 5, 2009
 at U
niversity of A
berdeen on A
ugust 27, 2015
http://hm
g.oxfordjournals.org/
D
ow
nloaded from
 
nine new putative RA susceptibility loci, in addition toHLA and
PTPN22 (3). One single nucleotide polymorphism (SNP)
located in the chromosomal region 6q23, rs6920220, was
unequivocally replicated in a validation study (4). Interestingly,
association to the same SNP and a second, independently
associated polymorphism in the region (rs10499194) was
detected in a GWAS in a US population, confirming the locus
as important in RA causation (5). Increased risk for RA is con-
ferred by the minor allele of rs6920220 and protection by the
minor allele of rs10499194. The effect size for both these
alleles is relatively small (OR 1.22 and OR 0.75, respectively).
Both associated variants map to an intergenic region of 6q23,
between the OLIG3 and TNFAIP3 genes. OLIG3 is involved
in the development and differentiation of neuronal cells and
therefore not an obvious candidate gene for RA (6). Conversely,
A20, the product of TNFAIP3, is a potent anti-inflammatory
protein, since it is required for the termination of both tumor
necrosis factor (TNF) and Toll-like receptor-induced NF-kB
signals (7,8). In addition, A20 deficient mice develop severe
inflammation, which includes inflammation of the joints (9).
Therefore, TNFAIP3 seems a robust candidate gene for RA sus-
ceptibility. However, interrogation of data available from
public databases shows no correlation between genotype at
either SNP and TNFAIP3 expression in PBMCs (10). Identifi-
cation of variants within the TNFAIP3 gene itself which were
associated with RA susceptibility would lend support to the
hypothesis that the intergenic region exerts its effect through
regulation of this locus. The failure to identify correlation
between genotype and expression may arise if the associated
SNPs are in only modest LD with the true causal variants.
Hence, the aim of the current study was to undertake fine-
mapping of the 6q23 region in order to search for additional
disease-associated variants both within the intergenic block
encompassing the RA-associated SNPs and across the
TNFAIP3 gene itself.
RESULTS
Three thousand nine hundred and sixty-two RA patients and
3531 healthy controls were genotyped for 70 SNPs in two
regions within the 6q23 locus defined by recombination rate
and LD. The first region spanned the LD block containing
the rs6929220 SNP, association of which had previously
been validated with RA susceptibility. This variant maps to
an intergenic region but it was hypothesized that it may
exert its functional effect via the TNFAIP3 gene. Hence, fine
mapping of this gene was also undertaken.
We found 18 SNPs associated with RA, trend P-value ,
0.05 (Fig. 1 and Supplementary Material, Table S1). The
SNPs showing the strongest association with RA remained
rs6920220 [P ¼ 2.61  1027, OR (95% CI) 1.22 (1.13–
1.32)] and the three SNPs (rs2327832, rs6933404 and
rs6927172) in r2 ¼ 1 with that variant. The next most strongly
associated polymorphisms were the SNPs rs13207033 [P ¼
0.0001, OR (95% CI) 0.86 (0.80–0.93)], rs13192841 and
rs1257282 all of which were perfectly correlated (r2 ¼ 1)
with rs10499194. As in the previous study, the minor allele
was associated with protection against RA (5). This represents
the first independent replication of the association of the
rs10499194 polymorphism with RA susceptibility. Addition-
ally, we found a number of new potential RA markers,
including rs5029937, located in the intron 2 of TNFAIP3.
The LD pattern among the markers included in this study
showed the presence of seven different blocks (Fig. 2). The
most strongly associated SNPs are located in Block 2 which
lies in the intergenic region between OLIG3 and TNFAIP3,
spanning 63 kb and located between positions 138002057
and 138064935 of chromosome 6q. Haplotype analysis with
Block 2 SNPs yielded six common haplotypes with frequency
.5% (Table 1). Haplotype 1, tagged by the most strongly
associated SNP in the single-point analysis, rs6920220 (high-
lighted in red), confers risk for RA [P ¼ 1.8  1026, OR (95%
CI) 1.22 (1.13–1.33)], while Haplotype 2, tagged by
rs13207033 and rs1878658 (highlighted in blue and green,
respectively), is associated with protection [P ¼ 6  1025,
OR (95% CI) 0.83 (0.76–0.91)]. The associated SNP in
intron 2 of the TNFAIP3 gene, rs5029937, is located in a
different LD block spanning 71 kb, but we found no evidence
for a haplotypic effect of SNPs in this block.
In order to determine whether the three effects observed were
independent or not, conditional logistic regression analysis was
undertaken. The 18 associated markers were conditioned on the
effect of each of the other associated SNPs. Only three SNPs,
rs6920220, rs13207033 and rs5029937, remained significant
after conditioning on each associated marker (Table 2) and
the results showed that, rs1878658, one of the SNPs tagging
the protective haplotype, was not significantly associated with
RA after conditioning on rs13207033. This suggests that each
of the 3 SNPs is exerting an independent effect. As an
additional test for independence, we conditioned the effect of
the associated SNPs on both rs6920220 and rs13207033.
Only the rs5029937 SNP showed significant association
(P-value ¼ 0.02, after conditioning on both rs6920220 and
rs13207033). To further test the independent effect of the
intron 2 SNP, rs5029937, we repeated the conditional logistic
regression pooling the validation data from this study with
that obtained from the previous WTCCC GWAS for RA (3)
with the aim of increasing the statistical power, since allele fre-
quencies were similar across both groups and there was no
overlap in samples between these two cohorts. We used
imputed data for rs5029937 in the WTCCC cohort, given that
this SNP was not included in the initial GWAS (imputation
confidence score 0.99). This polymorphism showed a highly
significant association with RA after conditioning on
rs6920220, rs13207033 and both (P-values 4.71  10211,
6.95  1026 and 7.59  1026, respectively).
For exploratory purposes, we performed a stepwise logistic
regression analysis. The method begins with an empty model
to which variables are added in an iterative process. This
analysis showed that rs6920220 exhibits the strongest associ-
ation with RA. Subsequent additions of rs5029937 and
rs13207033 significantly improve the model, adding further
evidence to support that multiple polymorphisms in the 6q23
region are independently associated with RA (Table 3).
Stratification analysis of the three independently associated
RA SNPs showed that all three SNPs were associated with
both male and female RA cases (Supplementary Material,
Table S3). rs6920220 and the intron 2 SNP, rs5029937,
appeared to be associated with auto-antibody positive cases,
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with strong association in both RF positive and anti-CCP
positive cases. In contrast, rs13207033 was associated with
both RF positive and negative RA cases, but only anti-CCP
negative cases. Further studies in larger cohorts will be required
in order to clarify the role of these polymorphisms with auto-
antibody status, as only a subset of individuals with available
serological data was included in the present analysis.
In order to determine the combined contribution to the risk
of developing RA, logistic regression analysis was undertaken
(Table 4). Loci were defined as carriage of the minor risk
alleles A and T at rs6920220 and rs5029937, respectively,
combined with the different genotypes of the protective SNP
rs13207033. In order to avoid a loss of power due to the
high degree of stratification, we pooled the validation data
from this study with that obtained from the previous
WTCCC GWAS for RA (3). For OR calculations, the refer-
ence was the lowest risk combination. The combination of
the carriage of both risk alleles of rs6920220 and rs5029937
together with the absence of the protective allele of
rs13207033 was strongly associated with RA when compared
with carriage of none [OR of 1.86 (95% CI) (1.51–2.29)]. This
equates to an effect size of 1.50 (95% CI 1.21–1.85) compared
with controls and is higher than that obtained for any SNP
individually (4.4% of the RA patients versus 2.3% of the con-
trols carried this high-risk combination).
DISCUSSION
We present evidence that the recently described RA suscepti-
bility locus at 6q23 contains at least three independent effects,
two conferring susceptibility (rs6920220 and rs5029937) and
one protection (rs13207033). Carriage of both susceptibility
alleles and absence of protective alleles confers a far greater
risk for RA compared with the effect size initially assigned
to this locus.
The P-value for rs5029937 in the single point analysis (P ¼
0.001), although statistically significant, is not as impressive
Figure 1. Case–control association results of the OLIG3/TNFAIP3 region. The blue diamond indicates the strongest signal from the fine-mapping, i.e rs6920220.
For the rest of the SNPs, the colour indicates the extent of LD with rs6920220 (red: r2. 0.8, orange: 0.5 r2,0.8, yellow: 0.5. r2  0.2, white: r2, 0.2).
Figure 2. LD in the 500 kb region analysed, shown as r2 values, and location of the three independently associated SNPs.
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as those found for rs6920220 and rs13207033 and would not
have remained significant had a very conservative Bonferroni
correction to account for 70 independent tests been applied.
However, a number of statistical analyses each support an
independent effect of this SNP. First, P-values obtained
from the conditional analyses are statistically significant. Sec-
ondly, the stepwise logistic regression also suggested an inde-
pendent effect at this SNP (P ¼ 0.04). Finally, the
combination analysis (Table 4) showed a substantial increase
in the OR (from 1.42 to 1.86) when adding the rs5029937 sus-
ceptibility T allele to the carriage of the rs6920220 risk allele
and the absence of the rs13207033 protective allele. The lack
of LD with the previously described RA susceptibility markers
in the 6q23 region adds further evidence to support the inde-
pendent effect of rs5029937. The results provide convincing
evidence to support a third allele in the 6q23 region but repli-
cation in an independent cohort is required to confirm this
unequivocally.
The present work constitutes only the first stage of the com-
plete study of the 6q23 chromosomal region. We restricted our
fine-mapping to the region surrounding the rs6920220 SNP
that was detected in the second tier of significance of our pre-
vious GWAS (P ¼ 102525  1027) and to fine-mapping the
TNFAIP3 gene, since it was the most suggestive candidate
gene in the neighbouring region. Although we found three
independent variants associated with RA, it is possible that
the locus harbours additional independent RA markers, as we
did not explore the entire region. In fact, the haplotype data
obtained in the present study support this hypothesis. For
example, the haplotype analysis showed that haplotypes 1 and
2 were associated with susceptibility to and protection against
RA, respectively. This was in accordance with the results
found by Plenge et al. (5). However, haplotype 6, which was
associated with protection in the study by Plenge et al. (5),
was neutral in our study. rs13207033 tags haplotypes 2 and 6
and, therefore, it seems that the presence of the protective A
allele of rs13207033 is not sufficient to provide protection for
RA. The SNPs included in this study were able to capture
89% of the variation within this LD block. Therefore, additional
SNPs not tagged in the current study might be involved in the
protective effect together with rs13207033.
Interestingly, several markers in the TNFAIP3 region have
recently been shown to be associated with the related auto-
immune disease, systemic lupus erythematosus (SLE), in
two independent studies (11,12). However, the results were
conflicting. The SNP showing the strongest association with
RA in the present study, rs6920220, was also associated
with SLE in the study by Graham et al. (11), but it failed to
show independent association with SLE in the study by
Musone et al. (12) after conditional analysis. Conversely,
Graham et al. (11) did not find evidence for association for
the rs10499194 RA protective SNP, whereas Musone et al.
(12) found that rs13192841 (a perfect proxy of rs10499194)
was the most strongly associated variant in their cohort.
Despite this disagreement, it is clear that the TNFAIP3
region plays an important role in SLE, as both studies found
additional markers significantly associated with the disease
including the functional exon 3 rs2230926 polymorphism.
Interestingly, this variant was not independently associated
with RA in our study. A recent robust study has shown thatT
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rs6920220 and rs10499194 are also independently associated
with T1D (13). Moreover, a GWAS has demonstrated strong
association of the TNFAIP3 with psoriasis (14). These findings
confirm the importance of the 6q23 locus. Future studies will
be required to ascertain whether RA, SLE and T1D are associ-
ated with the same or different causative variants within the
6q23 region, and whether the locus harbours risk alleles for
other auto-immune or inflammatory diseases.
A consistent observation from successful GWAS is that the
effect sizes of new loci are small (OR, 1.2) and that the com-
bined effect of all known loci can account for only a fraction
of the genetic risk of disease. This may be because very large
numbers of as yet undefined loci explain complex traits, but
may also be explained by a significant underestimation of
risk for new loci. Re-sequencing and fine mapping studies
may be essential in order to identify all risk/protective
alleles at a locus and only once the effect of combinations
of these are assessed can the true risk for a given locus be
ascribed. Here we demonstrate that this is indeed the case
for the recently described RA locus at 6q23, for which we
have characterized three independent effects that can increase
the risk from 1.22 to 1.50, establishing 6q23 as the next most
important locus for RA in a UK population alongside
HLA-DRB1 and PTPN22.
MATERIALS AND METHODS
In order to search the 6q23 region for additional disease variants,
we analysed a panel of 70 SNPs across chromosome 6q23
encompassing two regions defined by recombination rate and
LD blocks. The first region contained the strongest signal
(rs6929220) and spanned the LD block around it from position
137990000 to 138090000. The second encompassed the
TNFAIP3 gene from position 138215000 to 138300000, where
we had suggestive evidence of independent effects (Fig. 2).
Tagging SNPs across the blocks were selected with a minor
allele frequency (MAF) . 0% and r2 ¼ 0.8 and were enriched
with proxies for known susceptibility SNPs (rs6920220 and
rs10499194). Statistical power to detect effect sizes between
1.15 and 2.00 was .80% at a 5% significance level.
Patients with RA (n ¼ 3962) were recruited from six centres
(Manchester, Sheffield, Leeds, Aberdeen, Oxford and London)
across the UK. All cases were Caucasian of Northern Euro-
pean descent and all fulfilled the 1987 American College of
Rheumatology classification criteria modified for genetic
studies (15,16). Clinical and demographic characteristics of
the cohort are detailed in Supplementary Material, Table S1.
Briefly, 72% subjects were female, 72% were rheumatoid
factor positive and 67% carried ACPA antibodies as recog-
nized by the anti-CCP antibody test. Therefore, this cohort is
representative of a hospital-based series of RA subjects.
Healthy controls (n ¼ 3531) were recruited from five of the
six centres (cases only recruited from London). All partici-
pants were recruited after providing informed consent and
the study was approved by the North West Research Ethics
Committee (MREC 99/8/84).
Serum RF and anti-CCP antibody titre were measured using
commercially available kits [RF-PAIA Immunoturbidimetric
Assay for rheumatoid factor, DiastatTM Anti-CCP Kit (Axis-
Shield Diagnostics Limited, UK)]. Patients with titres
40 units/ml and 5 units/ml were defined as positive for
RF and anti-CCP antibodies, respectively.
Genotyping was performed using the Sequenom iPlex plat-
form (www.sequenom.com) according to the manufacturer’s
instructions. All genotyping was performed at the arc
Table 2. Conditional logistic regression analysis for all SNPs with single-point allelic P , 0.05
SNP Position Unconditioned
P-value
P-value conditional on
rs6920220
P-value conditional on
rs13207033
P-value conditional on rs6920220 and
rs13207033
rs590523 137992570 0.006 0.214 0.049 0.282
rs6933404 138000928 5.71  10206 0.957 0.0002 0.715
rs9389526 138002555 0.01 0.996 0.435 0.164
rs13207033 138007111 0.0001 0.011 — —
rs13192841 138008907 0.0003 0.014 Collinear —
rs12527282 138008945 0.0004 0.009 Collinear —
rs2327832 138014761 1.01  10206 0.65 0.0003 0.506
rs1878658 138020079 0.0003 0.021 0.495 0.283
rs2069311 138022920 0.02 0.007 0.111 0.01
rs678385 138034243 0.002 0.736 0.354 0.464
rs665668 138038578 0.0008 0.546 0.202 0.593
rs6927172 138043868 7.20  10206 Collinear 0.0005 —
rs6920220 138048197 2.61  10207 — 8.77  1025 —
rs636393 138049223 0.0007 0.079 0.449 0.903
rs508214 138055358 0.001 0.106 0.536 0.686
rs5029937 138236844 0.001 0.041 0.019 0.02
rs2230926 138237759 0.03 0.274 0.141 0.222
rs6932056 138284130 0.04 0.442 0.223 0.336
Collinear, one allele determines the other in .99% of haplotypes.
Table 3. Stepwise logistic regression of three SNPs model
SNP added to the model P-value OR (95% CI)
rs6920220 0.001 1.04 (1.02–1.06)
rs5029937 0.042 1.11 (1.01–1.23)
rs13207033 0.049 0.98 (0.96–0.99)
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Epidemiology Unit, Manchester. Only samples and SNPs
exceeding a 90% success rate were used in the analysis.
Genotype counts in cases and controls were analysed using
PLINK software using the x2 test for trend (17). Stratification
analysis by gender, RF status and anti-CCP antibody status
was performed. Haplotype analysis was undertaken using the
software programs UNPHASED (18) and Haploview (19).
Conditional and stepwise logistic regression was used to deter-
mine whether independent effects existed. These analyses
were carried out utilizing STATA version 9.2.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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